We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-6.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$266M
AUM Growth
-$131K
Cap. Flow
+$22.7M
Cap. Flow %
8.53%
Top 10 Hldgs %
48.53%
Holding
95
New
9
Increased
25
Reduced
15
Closed
6

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$7.86M
2
APLS
Apellis Pharmaceuticals
APLS
+$4.67M
3
TVRD
Tvardi Therapeutics
TVRD
+$4.02M
4
ALEC icon
Alector
ALEC
+$2.2M
5
MGNX icon
MacroGenics
MGNX
+$2.16M

Top Sells

Rank Stock Value
1
QNCX icon
Quince Therapeutics
QNCX
+$2.78M
2
INDP icon
Indaptus Therapeutics
INDP
+$1.8M
3
NXTC icon
NextCure
NXTC
+$1.44M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$1.41M
5
ARGX icon
argenx
ARGX
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 92.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
26
Ardelyx
ARDX
$1.22B
$2.73M 1.03%
580,524
-101,235
-15% -$352K
MGNX icon
27
MacroGenics
MGNX
$235M
$2.55M 0.96%
200,000
+150,000
+300% +$2.16M
ARGX icon
28
argenx
ARGX
$53.4B
$2.5M 0.94%
21,969
-9,781
-31% -$1.32M
BLUE
29
DELISTED
bluebird bio
BLUE
$2.34M 0.88%
1,969
– –
KDMN
30
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.23M 0.84%
886,177
– –
CSII
31
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.19M 0.83%
46,200
-5,000
-10% -$235K
ALEC icon
32
Alector
ALEC
$168M
$2.09M 0.79%
145,000
+121,834
+526% +$2.2M
ARAY icon
33
Accuray
ARAY
$32M
$1.87M 0.7%
674,300
+150,000
+29% +$498K
BEAT
34
DELISTED
BioTelemetry, Inc.
BEAT
$1.84M 0.69%
45,300
– –
NVRO
35
DELISTED
NEVRO CORP.
NVRO
$1.82M 0.69%
21,210
-5,000
-19% -$378K
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
$1.79M 0.67%
349,996
– –
ARCT icon
37
Arcturus Therapeutics
ARCT
$164M
$1.79M 0.67%
173,914
+171,514
+7,146% +$1.85M
TPTX
38
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.78M 0.67%
+47,308
New +$2.06M
DRNA
39
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.7M 0.64%
118,314
– –
ELOX
40
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$1.7M 0.64%
9,375
– –
ACHN
41
DELISTED
Achillion Pharmaceuticals
ACHN
$1.58M 0.59%
438,884
-166,000
-27% -$640K
GNCA
42
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.57M 0.59%
542,564
-191,858
-26% -$655K
KURA icon
43
Kura Oncology
KURA
$800M
$1.57M 0.59%
103,658
+56,416
+119% +$1M
PRQR icon
44
ProQR Therapeutics
PRQR
$243M
$1.51M 0.57%
261,521
– –
PHAS
45
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.5M 0.57%
360,542
+160,529
+80% +$1.28M
AGTC
46
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.49M 0.56%
359,190
– –
CRBP icon
47
Corbus Pharmaceuticals
CRBP
$166M
$1.45M 0.54%
9,910
– –
VKTX icon
48
Viking Therapeutics
VKTX
$3.7B
$1.44M 0.54%
209,200
– –
BCRX icon
49
BioCryst Pharmaceuticals
BCRX
$2.28B
$1.39M 0.52%
483,388
+72,500
+18% +$226K
NTUS
50
DELISTED
Natus Medical Inc
NTUS
$1.37M 0.51%
42,900
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, DAFNA Capital Management held 95 positions worth $266M, down 0.05% from $266M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management deployed $22.7M of net new capital in Q3 2019, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, an estimated $1.41M trimmed.

  • DAFNA Capital Management's largest Q3 2019 buy was Apellis Pharmaceuticals: 169,800 shares worth $4.09M.
  • DAFNA Capital Management added most to Fate Therapeutics in Q3 2019, an estimated $7.86M increase.
  • DAFNA Capital Management's biggest Q3 2019 reduction was Foamix Pharmaceuticals Ltd. Ordinary Shares, cutting an estimated $1.41M.
  • DAFNA Capital Management fully exited Quince Therapeutics in Q3 2019, selling an estimated $2.78M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $266M portfolio in Q3 2019.
  • DAFNA Capital Management opened 9 new positions and closed 6 in Q3 2019.
  • DAFNA Capital Management's portfolio value fell 0.05% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.